Merck (MRK) Stock Looks Below Fair Value On Cash Flow But Fair On Earnings
Merck stock has more than doubled over the past five years, yet the latest valuation checks send a mixed message, with the Discounted Cash Flow (DCF) estimate pointing to meaningful upside while market based multiples look closer to in line.
- Merck has returned 101.7% over 5 years, which puts the current share price in a very different place to where long term holders started.
- Progress on products such as the once monthly HIV PrEP candidate alimatravir and expanded use of KEYTRUDA can support cash flow expectations, while competition from generics and new therapies in key disease areas may pressure future pricing power.
- Merck scores 3 out of 6 on the valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.
The stock's next move may depend on whether the current US$130.20 price already reflects that intrinsic value upside or still leaves a margin of safety for Merck shareholders.
Does Merck Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Merck might be worth based on the cash it is expected to generate for shareholders. Merck is currently producing last twelve month free cash flow of about $14.0b, and the model assumes that these cash flows keep growing rather than shrinking over time. On that basis, the DCF points to an estimated intrinsic value of about $228 per share.
Compared with the current share price of $130.20, the DCF output suggests Merck stock trades at roughly a 43.0% discount to this intrinsic value, which screens as undervalued on this measure. The recent update on access plans for alimatravir in HIV prevention is one factor used in the model to support a robust cash flow outlook, even if the market is not fully pricing that potential in yet.
On the DCF model alone, Merck stock currently appears undervalued relative to its projected cash flows.
Our Discounted Cash Flow (DCF) analysis suggests Merck is undervalued by 43.0%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.
Where Does Merck Sit on Earnings?
P/E is a useful lens for Merck because earnings remain a key anchor for how the market prices large pharmaceutical stocks. Merck currently trades on a P/E of about 36.0x, compared with a pharmaceuticals industry average of around 15.4x and a peer group average near 25.8x. On simple comparisons, that is a clear premium to both the wider industry and closer large cap peers.
The fair P/E ratio for Merck, which blends in factors such as its margins, risk profile, size and expected earnings path, is estimated at about 36.2x. That sits very close to the current 36.0x multiple, so the gap between price and this modelled anchor is small despite the higher level relative to industry averages.
Putting these pieces together, Merck stock currently appears to be priced roughly in line with what the P/E framework indicates as fair.
See what the numbers say about this price — find out in our valuation breakdown.
The Merck Narrative: What Would Justify Today's Price?
Merck's valuation picture raises clear questions about what needs to happen next on growth, margins and earnings for the stock to move meaningfully away from today's price. This is where Simply Wall St Narratives come in as a bridge. Narratives on the Community page spell out competing stories for Merck's future and link each scenario to a specific number, anchored in a view on how the company's growth profile, profitability and risks could evolve as new information emerges.
Community views on Merck are split between a pipeline driven upside story and a more cautious read on policy and concentration risk.
Bull case: roughly fairly valued
"With its acquisition and licensing strategy, Merck has nearly tripled its late-phase pipeline since 2021, which is expected to have a potential commercial opportunity of over $50 billion by the mid-2030s, driving earnings growth…"
Read the full Bull Case to see why Merck could be undervalued
Bear case: 20% overvalued
"Intensifying global pressure on drug pricing from policymakers, insurers, and patients, including the prospect of government-mandated price cuts and the impending impact of the Inflation Reduction Act, threatens to erode future revenue growth and compress net margins across Merck's flagship and pipeline products…"
Read the full Bear Case to see why Merck could be overvalued
Do you think there's more to the story for Merck? Head over to our Community to see what others are saying!
The Bottom Line
For Merck, the Discounted Cash Flow (DCF) view still points to meaningful intrinsic value upside, while the P/E based assessment argues the stock now sits close to what the market considers fair. That split reflects different sensitivities, with the DCF leaning heavily on long term cash flow durability and the multiple view anchored in current sentiment and peer pricing. Given the mixed score across broader valuation checks, the key question is whether Merck can sustain the earnings and cash generation that the intrinsic value estimate assumes, particularly in the context of pricing pressure and competition in key therapies.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com